



AACR Special Conference

Advances in Prostate Cancer Research

March 15-18, 2023 | Denver, CO

AACR
American Association
for Cancer Research®

221001E

Proffered Presentations

**current as of 3/4/2023*

PR001, A042 An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and AR therapy resistance. Ping Mu, UT Southwestern Medical Center, Dallas, Texas.

PR002 Loss of protein phosphatase PP2A activity drive AR addiction in prostate cancer. Irfan A. Asangani, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PR003, A050 Convergent evolution in DNA repair-deficient mCRPC in response to targeted therapy. David A. Quigley, University of California, San Francisco, California.

PR004, B009 Exploring the role of ASCL1 in neuroendocrine prostate cancer. Kathia E. Rodarte, UT Southwestern Medical Center, Dallas, Texas.

PR005 Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutations. Samantha L. Schuster, Fred Hutchinson Cancer Center, Seattle, Washington.

PR006 PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer. Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

PR007, A003 ERG-driven luminal prostate cancers emerge from Ck5+/Nkx3.1+ basal cells. Weiran Feng, Memorial Sloan Kettering Cancer Center, New York, New York.

PR008 Molecular determinants of prostate cancer lineage plasticity. David W. Goodrich, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

PR009 Basal cell lineage plasticity in prostate homeostasis, repair and tumor initiation. Dong Gao, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China (Mainland).

PR010, B055 First-in-class TRPV6 inhibitors for the treatment of prostate cancer. Kimberley Beaumont, Uniquist, St. Lucia, Queensland, Australia.

PR011 The carcinoma of prostate sequencing of tumor and clinical endpoints (CAPSTONE) project: a clinico-genomic resource to enable patient-centric genomic research and improve the actionability of genetic testing in metastatic prostate cancer. Marcin P. Cieslik, University of Michigan, Ann Arbor, Michigan.

PR012 Ultra-sensitive detection of circulating tumour DNA enriches for patients with higher risk disease in clinically localised prostate cancer. Bernard J. Pope, The University of Melbourne, Melbourne, Victoria, Australia.

PR013, B043 Unlocking the proteome of metastatic prostate cancer circulating tumor cells. Justin M. Drake, University of Minnesota-Twin Cities, Minneapolis, Minnesota.

PR014 Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Li Jia, Brigham and Women's Hospital, Boston, Massachusetts.

PR015 Inhibition of androgen receptor signaling in castrate resistant prostate cancer in association with inhibition of glycolysis by targeting hexokinase 2 activity with pyrrolopyrimidine-based small molecules. Takuma Uo, University of Washington, Seattle, Washington.